In any case, this is part of the information that the National Institute of Public Health of Quebec (INSPQ) transmitted to the office of the Member of Parliament for Jonquière, Yannick Gagnon, who took charge of Ms. Desmeules’ file.
A few days ago, the Jonquiéroise confided to Daily experience injustice by being refused access to this medicine which can improve her daily life, under the pretext that she has received a lung transplant. She didn’t know the logical reasons behind this decision. She therefore contacted Yannick Gagnon to advance her case.
Ann Julie Desmeules cannot access the medication that could improve her life due to a lung transplant. (Ann Julie Desmeules)
The latter immediately contacted his colleague Christian Dubé to obtain more information, while his office contacted the RAMQ to find out more about Trikafta.
“As soon as I received Ms. Desmeules’ letter, we undertook a series of actions to see the possibilities to improve her life. Obviously, this is not a matter that can be resolved like a letter in the post. You have to gather a lot of information and make sure you have all the elements to then see if there are any possibilities. We are in contact with the lady and it is a file that I am monitoring very closely and which continues to progress. My goal is that she can quickly get news,” mentioned Yannick Gagnon.
The deputy for Jonquière, Yannick Gagnon, took charge of Ann Julie Desmeules’ file and is awaiting feedback from the INSPQ and the RAMQ. (Tom Core/Archives The Daily)
Around mid-December, a first part of the response was obtained. According to information received from the INSPQ, the institute does not recommend the use of Trikafta for lung transplant recipients. But the office is still waiting for other information to know why this medication is not recommended for them.
Trikafta, an “almost miraculous” treatment for people with cystic fibrosis, is not recommended for people with lung transplants, according to the INSPQ. (Canadian Press Archives/Canadian Press Archives)
“The INSPQ does not recommend it, and we do not know on what basis her doctor tells her that it would be beneficial for her,” adds Pierre-Luc Desbiens, the director of the MP’s office and communications. When we have the arguments why it is not recommended, we will be able to see based on its file to, perhaps, make it an exceptional medicine. »
He assures that from the beginning of January, the office will follow up with the ministries regarding all the files awaiting a response, and that that of Ms. Desmeules is a priority.
